---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-000125"
form_type: "8-K"
ticker: "TECH"
cik: "0000842023"
company_name: "BIO-TECHNE Corp"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:45:35.482490+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Bio-Techne appoints Matthew McManus as President DGS; Kim Kelderman to become CEO Feb 1, 2024

## Summary
- Matthew McManus appointed President – Diagnostics and Genomics Segment, effective Jan 8, 2024.
- McManus receives $550K base salary, 90% target cash incentive, $950K RSU grant, and other equity awards.
- McManus succeeds Kim Kelderman, who will become Bio-Techne CEO effective Feb 1, 2024.
- Employment agreement has three-year initial term; severance equal to one year base salary plus prorated incentive.
- McManus previously led Bio-Techne's Molecular Diagnostics Division after Asuragen acquisition.

## SEC filing metadata
- accession: 0001558370-24-000125
- form_type: 8-K
- ticker: TECH
- cik: 0000842023
- company_name: BIO-TECHNE Corp
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/842023/000155837024000125/0001558370-24-000125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/842023/000155837024000125/tmb-20240105x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-000125
- JSON: https://secwatch.observer/filing/0001558370-24-000125.json
- Plain text: https://secwatch.observer/filing/0001558370-24-000125.txt

## Key facts
- Executive change
  Dr. Matthew McManus was appointed as President – Diagnostics and Genomics Segment at BIO-TECHNE Corp.
  - Action: appointed
  - Role: President – Diagnostics and Genomics Segment
  source text: On January 5, 2024, Bio-Techne Corporation (the “Company”) announced the appointment of Dr. Matthew McManus, age 55, as President – Diagnostics and Genomics Segment (“President DGS”) effective January 8, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/842023/000155837024000125/0001558370-24-000125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.